Get the Stockscreener App
2.4308
32.97%
0.6108
Zyversa Therapeutics Inc stock is traded at $2.4308, with a volume of 60.74M.
It is up +32.97% in the last 24 hours and up +8.04% over the past month.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
See More
Previous Close:
$1.82
Open:
$2.66
24h Volume:
60.74M
Relative Volume:
57.83
Market Cap:
$2.59M
Revenue:
-
Net Income/Loss:
$-98.30M
P/E Ratio:
-0.3372
EPS:
-7.2097
Net Cash Flow:
$-8.72M
1W Performance:
+18.63%
1M Performance:
+8.04%
6M Performance:
-55.60%
1Y Performance:
+175.63%
1-Day Range:
$2.3501
$3.37
1-Week Range:
$1.82
$3.37
52-Week Range:
$0.541
$30.30
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Name
Zyversa Therapeutics Inc
Sector
Industry
Phone
908-370-5102
Address
217 W. MAIN STREET, SOMERVILLE
Zyversa Therapeutics Inc Stock (ZVSA) Latest News
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
ZyVersa reports progress on obesity inflammation treatment By Investing.com - Investing.com UK
ZyVersa Therapeutics Highlights Published Data - GlobeNewswire
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes - StockTitan
ZyVersa Therapeutics Highlights Review Article Supporting - GlobeNewswire
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs - StockTitan
ZyVersa reports obesity-linked brain inflammation study By Investing.com - Investing.com Canada
ZyVersa reports obesity-linked brain inflammation study - Investing.com
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases - GlobeNewswire
ZVSA stock touches 52-week low at $2.07 amid sharp annual decline - Investing.com Canada
ZVSAZyVersa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
ZyVersa advances obesity drug with key milestones ahead - Investing.com India
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months - The Manila Times
ZyVersa advances obesity drug with key milestones ahead By Investing.com - Investing.com UK
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter - GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured - GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to - The Bakersfield Californian
ZyVersa forms new SAB for obesity treatment advancement By Investing.com - Investing.com South Africa
ZyVersa forms new SAB for obesity treatment advancement - Investing.com India
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications - The Manila Times
ZyVersa Therapeutics Forms New Scientific Advisory Board to - GlobeNewswire
ZVSA stock touches 52-week low at $2.4 amid sharp annual decline - Investing.com UK
BTK Inhibitors Market to Observe Stunning Growth by 2034 | DelveInsight - PR Newswire UK
Thinking about buying stock in Visa Inc, Delta Air Lines, Barnes - GuruFocus.com
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Up 68.3% in July - Defense World
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa progresses with inflammation treatment IC 100 - Investing.com
ZyVersa progresses with inflammation treatment IC 100 By Investing.com - Investing.com UK
ZyVersa Therapeutics Announces Published Data Supporting - GlobeNewswire
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation - Yahoo Finance
Zyversa selects lead indication for ASC inhibitor IC-100 - BioWorld Online
ZyVersa Therapeutics Announces Published Data Demonstrating - GlobeNewswire
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults - StockTitan
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Update - Defense World
ZyVersa sets obesity as focus for new drug IC 100 - Investing.com
ZyVersa sets obesity as focus for new drug IC 100 By Investing.com - Investing.com Nigeria
Zyversa Therapeutics names lead indication for inflammasome ASC inhibitor - BioWorld Online
ZyVersa Therapeutics Selects Obesity and Related Metabolic - GlobeNewswire
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100 - Yahoo Finance
Market Momentum: ZyVersa Therapeutics Inc (ZVSA) Registers a -10.80 Decrease, Closing at 3.88 - The Dwinnex
ZyVersa Therapeutics Inc (ZVSA) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model - StockTitan
ZyVersa Therapeutics Announces Publication Demonstrating - GlobeNewswire
Short Interest in ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Decreases By 46.0% - American Banking and Market News
ZyVersa Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited - GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024 - Yahoo Finance
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update - Quantisnow
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal ... - Quantisnow
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 - Quantisnow
ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease - Quantisnow
Zyversa Therapeutics Inc Stock (ZVSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):